Literature DB >> 3377642

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.

M Davidson1, K L Davis.   

Abstract

Plasma homovanillic acid concentrations, a potential index of central dopamine turnover, were examined in normal control subjects and chronic schizophrenic patients over a 12-hour period, including the period of sleep. Plasma homovanillic acid concentrations were lower in schizophrenic patients compared with normal controls at all times; however, within the group of schizophrenics, the more symptomatic patients had higher plasma homovanillic acid concentrations than the less severely ill patients. These data are consistent with a more complex role of dopamine in schizophrenia than was previously conceptualized.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377642     DOI: 10.1001/archpsyc.1988.01800300057006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.

Authors:  J A Den Boer; D P Ravelli; J Huisman; J Ohrvik; W M Verhoeven; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions.

Authors:  R S Kahn; M Davidson; P Kanof; R T McQueeney; R R Singh; K L Davis
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Authors:  Christine Mohr; Theodor Landis; H Stefan Bracha; Marc Fathi; Peter Brugger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 4.  New perspectives on schizotypal personality disorder.

Authors:  R M Kirrane; L J Siever
Journal:  Curr Psychiatry Rep       Date:  2000-02       Impact factor: 5.285

5.  Concentrations of homovanillic Acid and gonadal hormones in the serum of male schizophrenic patients.

Authors:  S L Gong; J Wei; C N Ramchand; R Ramchand; G P Hemmings
Journal:  Indian J Psychiatry       Date:  1993-07       Impact factor: 1.759

Review 6.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

7.  Catatonia: short-term response to lorazepam and dopaminergic metabolism.

Authors:  G Northoff; J Wenke; L Demisch; J Eckert; B Gille; B Pflug
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

8.  Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: Window to the brain?

Authors:  M L Rao; B Strebel; G Gross; G Huber
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

9.  On the selection of mice for haloperidol response and non-response.

Authors:  R Hitzemann; K Dains; C M Bier-Langing; N R Zahniser
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 10.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.